Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 127 (3) , 369-376
Abstract
No abstract availableKeywords
Funding Information
- Macular Disease Foundation
- Bayer
- Novartis
This publication has 24 references indexed in Scilit:
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab InjectionsOphthalmology, 2014
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular DegenerationOphthalmology, 2014
- Is There Risk of Stroke with Aflibercept?Ophthalmology, 2014
- EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASESRetina, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmologica, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Fast Stable Restricted Maximum Likelihood and Marginal Likelihood Estimation of Semiparametric Generalized Linear ModelsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2010
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006